Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study)

Project Details

StatusActive
Effective start/end date24/09/20 → 31/03/26

Funding

  • Oslo University Hospital: A$184,259.00